TY - JOUR
T1 - Experience with pegylated interferon α -2a in advanced myeloproliferative neoplasms in an international cohort of 118 patients
AU - Gowin, Krisstina
AU - Thapaliy, Prakash
AU - Samuelson, Jan
AU - Harrison, Claire
AU - Radia, Deepti
AU - Andreasson, Bjorn
AU - Mascarenhas, John
AU - Rambaldi, Alessandro
AU - Barbui, Tiziano
AU - Rea, Catherine J.
AU - Camoriano, John
AU - Gentry, Amy
AU - Kiladjian, Jean Jacques
AU - O'Connell, Casey
AU - Mesa, Ruben
PY - 2012/10/1
Y1 - 2012/10/1
N2 - The Philadelphia negative myeloproliferative neoplasms, including polycythemia vera, essential thrombocythemia, and myelofibrosis, are associated with substantial vascular and transformative complications. Standard therapy for high-risk disease, particularly in patients that have failed initial therapy, remains controversial. Non-pegylated interferon has previously been shown to be effective in controlling erythrocytosis, thrombocytosis and thrombotic complications, but was found to have poor tolerability and excessive adverse effects. Recently, pegylated interferon alpha-2a was introduced and found to be better tolerated and less toxic than standard interferon. In addition, in recent phase II trials, pegylated interferon alpha-2a therapy was found to induce both hematologic and molecular remissions. We retrospectively analyzed 118 myeloproliferative patients who underwent pegylated interferon alpha-2a treatment. Responses were evaluated by ELN, IWG-MET and EUMNET standardized criteria sets and adverse effects were analyzed.
AB - The Philadelphia negative myeloproliferative neoplasms, including polycythemia vera, essential thrombocythemia, and myelofibrosis, are associated with substantial vascular and transformative complications. Standard therapy for high-risk disease, particularly in patients that have failed initial therapy, remains controversial. Non-pegylated interferon has previously been shown to be effective in controlling erythrocytosis, thrombocytosis and thrombotic complications, but was found to have poor tolerability and excessive adverse effects. Recently, pegylated interferon alpha-2a was introduced and found to be better tolerated and less toxic than standard interferon. In addition, in recent phase II trials, pegylated interferon alpha-2a therapy was found to induce both hematologic and molecular remissions. We retrospectively analyzed 118 myeloproliferative patients who underwent pegylated interferon alpha-2a treatment. Responses were evaluated by ELN, IWG-MET and EUMNET standardized criteria sets and adverse effects were analyzed.
KW - Myeloproliferative neoplasms
KW - Pegylated interferon alpha-2a
KW - Response
UR - http://www.scopus.com/inward/record.url?scp=84867261125&partnerID=8YFLogxK
U2 - 10.3324/haematol.2011.061390
DO - 10.3324/haematol.2011.061390
M3 - Article
C2 - 22419578
AN - SCOPUS:84867261125
SN - 0390-6078
VL - 97
SP - 1570
EP - 1573
JO - Haematologica
JF - Haematologica
IS - 10
ER -